Analyst Reco. Arena Pharmaceuticals BOERSE MUENCHEN

Equities

RN3N

US0400476075

Real-time BOERSE MUENCHEN Other stock markets			5-day change	1st Jan Change
- ^EUR	-.--%		+6.47%	+10.37%

2022	Longboard Pharmaceuticals, Inc. and Arena Pharmaceuticals, Inc. Executes into Second Amendment to That Certain License Agreement	CI
2022	Arena Pharmaceuticals, Inc.(NasdaqGS:ARNA) dropped from S&P Biotechnology Select Industry Index	CI

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

HC Wainwright Downgrades Arena Pharmaceuticals to Neutral From Buy; Price Target is $100	22-02-09	MT
Cantor Fitzgerald Downgrades Arena Pharmaceuticals to Neutral From Overweight, Adjusts Price Target to $100 From $93	21-12-21	MT
Citigroup Downgrades Arena Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $100 From $101	21-12-14	MT
Needham Downgrades Arena Pharmaceuticals to Hold From Buy, Drops $80 Price Target	21-12-14	MT
Credit Suisse Downgrades Arena Pharmaceuticals to Neutral from Outperform Following News of Sale to Pfizer, Raises PT to $100 from $98	21-12-14	MT
Wells Fargo Downgrades Arena Pharmaceuticals to Equal Weight From Overweight, Lifts Price Target to $100 From $71	21-12-14	MT
RBC Downgrades Arena Pharmaceuticals to Sector Perform From Outperform, Lifts Price Target to $100 From $76 Amid Pfizer Deal	21-12-14	MT
JMP Securities Downgrades Arena Pharmaceuticals to Market Perform From Market Outperform	21-12-14	MT
SVB Leerink Downgrades Arena Pharmaceuticals to Market Perform From Outperform; Price Target is $100	21-12-14	MT
Jefferies Downgrades Arena Pharmaceuticals to Hold From Buy, Price Target is $100	21-12-14	MT
ANALYST RECOMMENDATIONS : Adobe, eBay, Ford, Home Depot, Walmart...	21-12-14
Wells Fargo Starts Arena Pharmaceuticals at Overweight With $71 Price Target	21-12-08	MT
ARENA PHARMACEUTICALS : Cantor Fitzgerald Adjusts Arena Pharmaceuticals' Price Target to $93 From $100, Maintains Overweight Rating	21-08-10	MT
ARENA PHARMACEUTICALS : Credit Suisse Lowers Arena Pharmaceuticals' PT to $98 from $102, Notes Clinical Delays, Adjusts Expenses/Pipeline Projections; Keeps Outperform Rating	21-08-06	MT
ARENA PHARMACEUTICALS : EARNS 'A' RATING FROM MSCI ESG, A LEADING RATING AGENCY FOR SUSTAINABLE INVESTMENTS	21-06-04	AQ
Arena Pharmaceuticals : Earns "A" Rating from MSCI ESG, a Leading Rating Agency for Sustainable Investments	21-06-03	BU
ARENA PHARMACEUTICALS : Goldman Sachs Starts Arena Pharmaceuticals at Buy With $90 Price Target	21-05-18	MT
Arena Pharmaceuticals : Earns Prime Status from ISS ESG, a Leading Rating Agency for Sustainable Investments	21-05-12	BU
ARENA PHARMACEUTICALS : SVB Leerink Adjusts Arena Pharmaceuticals PT to $112 From $90, Maintains Outperform Rating	21-05-07	MT
ARENA PHARMACEUTICALS : Citigroup Starts Arena Pharmaceuticals at Buy With $104 Price Target	21-04-27	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Arena Pharmaceuticals BOERSE MUENCHEN

Equities

RN3N

US0400476075

Analyst Reco.

Filters